Key result
Monoclonal antibodies 7B3 and 14B1 protected 100% of K18-hACE2 mice from lethal SARS-CoV-2 WT and Delta variant challenges, and 7B3 provided therapeutic protection against Omicron BA.1 and BA.2.
Why the study?
Do monoclonal antibodies derived from early COVID-19 convalescents prevent lethal SARS-CoV-2 infection in K18-hACE2 KI mice?
Population
Two elite convalescents in Wuhan and K18-hACE2 KI mice
Comparison
Prophylactic and therapeutic human monoclonal antibodies (including 7B3 and 14B1) against SARS-CoV-2 challenge
Design
Preclinical in vitro and in vivo animal study
Authors
Loading...
Broadens candidate pool for variant-resistant mAbs; leaves open clinical translation and in vivo efficacy.
Do monoclonal antibodies derived from early COVID-19 convalescents prevent lethal SARS-CoV-2 infection in K18-hACE2 KI mice?
Absolute Event Rate: 100% vs 0%
Monoclonal antibodies 7B3 and 14B1 derived from early COVID-19 convalescents broadly neutralize SARS-CoV-2 variants and protect mice from lethal infection.
Liu et al. (2023) studied SARS-CoV-2 infection. Monoclonal antibodies 7B3 and 14B1 vs. Isotype control was evaluated on Survival rate at 8 days post-infection. Monoclonal antibodies 7B3 and 14B1 protected 100% of K18-hACE2 mice from lethal SARS-CoV-2 WT and Delta variant challenges, and 7B3 provided therapeutic protection against Omicron BA.1 and BA.2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: